Trillium Therapeutics Balance Sheet - Quarterly (NASDAQ:TRIL)

Add to My Stocks
$3.9 $0.18 (4.84%) TRIL stock closing price Oct 12, 2018 (Closing)

A thorough fundamental analysis involves using data from Trillium Therapeutics balance sheet, apart from other financial statements, to value the business. A balance sheet can help evaluate the financial performance of a company. Ratios like return on total assets and current ratio, which also uses cash on hand can be used to measure the operating efficiency of a firm, and can be used to conduct a more accurate Trillium Therapeutics stock analysis. Good quarterly results indicate a company's strong financial performance. Its important to check all financial statements including the balance sheet. Trillium Therapeutics had a long term debt of $- at the end of 2018 Q2. To understand the debt servicing capacity of the company, one needs to look at Trillium Therapeutics operating cash flow and Trillium Therapeutics revenue also. Trillium Therapeutics debt to equity ratio is .

View and download Trillium Therapeutics quarterly results to get the balance sheet details for the latest 40 quarters data.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q2
Marketable Securities31.83M35.21M41.21M28.86M26.01M9.52M---
Raw Materials---------
Work In Progress---------
Finished Goods---------
Notes Receivable---------
Other Current Assets1.5M--------
Total Current Assets
Property Plant & Equipment--3.48M---3.05M2.93M2.88M
Accumulated Depreciation--1.26M------
Net Property Plant & Equipment
Investment & Advances---------
Other Non-Current Assets---------
Deferred Charges---------
Deposits & Other Assets---------
Total Assets
Notes Payable---------
Accounts Payable10.56M10.81M10.87M7.93M6.65M5.03M4.16M3.44M3.06M
Current Portion Long-Term Debt---------
Current Portion Capital Leases---------
Accrued Expenses---------
Income Taxes Payable---------
Other Current Liabilities---------
Total Current Liabilities
Deferred Taxes/Income---------
Convertible Debt---------
Long-Term Debt---------
Non-Current Capital Leases---------
Other Long-Term Liabilities---1.77M1.66M1.98M1.81M1.67M1.74M
Total Liabilities
Minority Interest---------
Preferred Stock39.53M41.7M40.65M41.92M39.08M24.24M24.23M24.61M24.89M
Common Stock Net116.72M115.45M112.56M97.62M90.98M78.44M78.4M79.36M80.25M
Capital Surplus12.78M12.82M11.71M11.48M10.21M9.71M9.32M8.64M7.93M
Retained Earnings-126.31M-119.21M-109.62M-104.88M-89.33M-81.96M-73.27M-67.5M-62.15M
Treasury Stock---------
Other Liabilities5.03M5.14M5.3M5.49M5.12M5.2M5.2M5.31M5.37M
Shareholders Equity47.76M55.9M60.61M51.63M56.07M35.64M43.89M50.42M56.3M
Total Liabilities & Shareholders Equity59.64M68.07M72.82M61.78M64.82M43.09M50.31M55.99M61.64M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Apart from balance sheet items, an investor would do well to keep track of the Trillium Therapeutics stock price by looking at Trillium Therapeutics historical stock prices. One can compare PE with industry average by looking at the Trillium Therapeutics PE ratio chart. The common balance sheet items are:

  • Assets: An asset is a resource that a corporation like Trillium Therapeutics owns and has monetary significance. TRIL assets decreased from $68.07M in 2018 Q1 to $59.64M in 2018 Q2. Assets can be of two types: fixed assets like real estate, plant and machinery; and current assets which includes cash, accounts receivable etc. Tech stocks typically don't have too many assets.
  • Liabilities: The total liabilities of Trillium Therapeutics for the quarter 2018 Q2 total to $11.88M. Liabilities for a company like Trillium Therapeutics include bank loans, services which have been availed for which a settlement in the form of cash/ asset transfer needs to be done in future etc. A firm takes on such obligations to grow its business which in turn will generate future economic benefits for its business.

Trillium Therapeutics Balance Sheet - Key Ratios